18 results about "Hepatitis C" patented technology

A compound of the structure:or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

The hepatitis C detection device comprises a detection box, hepatitis C detection test paper, a blood taking needle, a hemostasis rod and an alcohol cotton ball, an observation window and a blood collection groove located below the observation window are formed in the front face of the detection box, a containing groove extending upwards is formed in one side of the bottom of the detection box, and a containing groove extending downwards is formed in the top of the detection box; the top of the detection box is covered with a cover body to form a sealed bin; the hepatitis C detection test paper is flatly laid in the detection box and corresponds to the observation window and the blood collection groove in position; a clamping ring is arranged on one side of the detection box, and the blood taking needle is embedded into the clamping ring; the hemostasis rod is inserted into the storage groove, and the end part of the hemostasis rod extends out of the storage groove; and the alcohol cotton ball is placed in the sealing bin. The blood taking needle, the hemostasis bar, the alcohol cotton ball and the like are integrated in the detection box, so that the use convenience is improved, the geographical limitation is relieved, and the detection box can be used in any occasion and is convenient and efficient.

To provide compounds, pharmaceutical compositions, and methods and uses to treat and / or prevent infections of HCV.SOLUTION: The present invention provides a compound with a structure (A) containing a specific substituent, or a pharmaceutically acceptable salt thereof, or a composition thereof.SELECTED DRAWING: Figure 4

The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, ebola, Zika, West Nile, Dengue, and HCV.

The invention discloses a sample liquid experiment table for hepatitis C virus detection, and relates to the technical field of virus detection, the sample liquid experiment table comprises a shell, a lifting mechanism and a cleaning mechanism; an opening is formed in the upper end of the shell, and a partition plate is horizontally fixed in an inner cavity; the mounting end of the driving assembly is fixed to the inner bottom wall of the shell, and the output end of the driving assembly penetrates through the partition plate. The pressing rod is fixed on the driving assembly; the placement plate and the detection mechanism can form a sealed space, and the bottom wall of the placement plate is fixedly connected with the output end of the driving assembly; the mounting end of the transmission assembly is fixed to the inner side wall of the shell, and the transmission end of the transmission assembly penetrates through the partition plate to be fixed to the elastic telescopic mechanism. The push plate surface is fixed at the other end of the transmission assembly; one end of the pressing plate is fixed to the transmission assembly, and the other end abuts against the pressing rod. In the hepatitis C detection process, it can be guaranteed that direct contact between an operator and a test tube can be reduced as much as possible in the detection process or after detection is completed, and some potential risks of the operator are avoided.

Described herein are methods and compositions relating to the inhibition of bile salt hydrolase (BSH) and uses thereof.SOLUTION: Provided herein are methods for treating metabolic disorders (e.g., diabetes, obesity), gastrointestinal diseases (such as gastrointestinal infections; inflammatory bowel diseases (IBD); appendicitis; Crohn's disease (CD); ulcerative cholitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetics; hepatits; hepatic diseases (such as non-alcoholic fatty liver disease (NAFLD); non-alcoholic fat hepatits (NASH); hepatits A; hepatits B; hepatits C; autoimmune hepatits; and cirrhosis of the liver); gastroesophageal reflux disease (GERD); celiac disease; diverticulitis; food intolerance; ulcers; infectious colitis; irritable bowel syndromes; intestinal wall leakage; and cancers); Methods for treating cancer (e.g., cancer of the digestive system, liver cancer) or inflammatory diseases (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcers, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to the subject a compound represented by Formulae (I) - (XVIII).SELECTED DRAWING: None

The application provides a hepatitis C antibody detection antigen composition and application, kit and detection method thereof, relates to the antibody detection technical field, and the hepatitis C antibody detection antigen composition comprises a labeled recombinant antigen and a coated recombinant antigen, the amino acid sequence of the labeled recombinant antigen includes Trx and hepatitis C Core region, NS3 protein, NS4b protein dominant epitope and His tag, and the full-length sequence is shown as SEQ ID NO. 1. The labeled recombinant antigen used in the application is obtained by mutating 7 cysteines (C) into alanine (A) by amino acid mutation on the NS3 protein, reducing the aggregation and precipitation caused by disulfide bond of the recombinant protein, and improving the protein stability. When colloidal gold is used for antigen labeling, a secondary indirect labeling method is adopted, which is beneficial to the exposure of antigen epitopes, can improve the reaction sensitivity, and reduces the antibody missed detection.

The invention belongs to the technical field of disease diagnosis and molecular biology, and particularly relates to application of LncRNA 02365 in HBV (Hepatitis B Virus) related HCC (Hepatitis C Chromatography) diagnosis. It is found for the first time that the LncRNA 02365 is abnormally high in expression in HBV-related HCC patients, the verification result of the serum-derived LncRNA 02365 and the verification result of the HBV-related HCC tissue are consistent, the sensitivity of the test result is high, and the specificity is good. Therefore, the LncRNA 02365 can be used as a molecular biomarker for diagnosing the HBV-related HCC, so that the disease risk of HBV-related HCC patients is predicted, high-risk groups are screened, and early and rapid non-invasive diagnosis is performed on the HBV-related HCC patients.

The invention discloses application of herba lycopi flavone in preparation of a medicine for treating HBV-HCC (Hepatitis B Virus-Hepatitis C Chromatography), and belongs to the technical field of biological medicines. In-vivo experiments prove that CP can effectively inhibit proliferation and metastasis of HBV-HCC (Hepatitis B Virus-Hepatitis C Chromatography) cells. In combination with in-vitro cell activity, it is proved that eupatorium flavone is the most bioactive component for inhibiting HBV-HCC cell growth, proliferation and metastasis in CP. By inhibiting the HIF-1alpha and the downstream effect of the HIF-1alpha on VEGFA signal transduction, angiogenesis induced by tumors is hindered, the growth of the tumors is limited, and the invasiveness of cancer cells is reduced, so that the possibility of metastasis is reduced. It is verified that the herba lycopi flavone can inhibit invasion and metastasis of HBV-HCC through an HBx / HIF-1alpha / VEGFA signal axis; growth and proliferation and cell metastasis of HBV-HCC cells are inhibited through an HIF-1alpha / VEGFA signal channel, so that a scientific basis is provided for anti-tumor of the herba lycopi flavone.

The application discloses a postpartum hepatitis C referral management system based on a mobile terminal and relates to the medical management field.The system comprises a medical communication module, a data entry module and an index preset module.The medical communication module is used for integrating the communication permission of the mobile terminal and providing a plurality of communication channels.The data entry module is used for periodically collecting and entering the liver function indexes, the hepatitis C virus load data and the emotional evaluation scores of puerpera through the medical communication module.The index preset module is used for presetting the benchmark feeding indexes of future periods according to a newborn growth model.The risk prediction module is used for collecting the data of the current period data entry module and the preset feeding indexes of the next period based on the risk prediction model.The risk coefficient of breastfeeding behavior is dynamically predicted by using the risk prediction model, the potential risks under different feeding schemes are quantitatively evaluated, the high-risk puerpera are early identified, the disease deterioration or the risk of mother-to-child transmission caused by delayed intervention is reduced, the human error is reduced, and the accuracy and response speed of postpartum hepatitis C management are improved.

The invention provides a hepatitis C antibody detection antigen composition and application thereof, a kit and a detection method, and relates to the technical field of antibody detection, the hepatitis C antibody detection antigen composition comprises a recombinant antigen for marking and a recombinant antigen for coating, the amino acid sequence of the recombinant antigen for marking comprises Trx and hepatitis C Core regions, NS3 protein, NS4b protein dominant epitopes and a His tag, and the full-length sequence is as shown in SEQ ID NO. 1. According to the recombinant antigen for marking, the NS3 protein is subjected to amino acid mutation to mutate seven cysteines (C) into alanine (A), aggregation and precipitation caused by disulfide bonds of the recombinant protein are reduced, and the protein stability is improved. When colloidal gold is labeled by the antigen, a secondary indirect labeling method is adopted, so that the exposure of antigen epitopes is facilitated, the reaction sensitivity can be improved, and the leakage detection of antibodies is reduced.

The utility model relates to a hepatitis C detection kit. The sampling part and the detection part are located in the box body, the sampling part comprises a capillary tube with oblique notches at the two ends, one end of the capillary tube can collect a detection sample, the other end of the capillary tube is inserted into a detection chamber with a vacuum cavity inside after collection is completed, and the detection sample is detected through detection test paper located in the detection chamber. According to the utility model, through the integrated design of collection and detection and the combination of the collection part and the detection part in the box body, the technical problem that the risk of leakage of samples carrying hepatitis C viruses is increased due to multiple steps and independent operation in the traditional hepatitis C detection process is solved.

The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis C infection, persistent hepatitis B infection or ethanol exposure induces a clinical Prognostic Liver Signature (PLS) high-risk gene signature. The cellular model system for hepatocellular carcinoma (HCC) / cirrhosis development and progression may be used in the screening of compounds useful in the treatment and / or prevention of cirrhosis and / or HCC as well as in the identification biomarkers for the prediction of liver disease (especially cirrhosis) progression and HCC. The present invention also relates to specific compounds that have been identified, using such screening methods, as useful in the treatment and / or the prevention of HCC / cirrhosis.

The utility model discloses a hepatitis C genetic typing detection experiment device which comprises a machine box, a transparent experiment box is fixed on one side of the machine box, ultraviolet sterilizing lamps are installed at the two ends inside the transparent experiment box respectively, operation openings are evenly formed in one side of the transparent experiment box, and the operation openings are connected with the machine box. A heat preservation storage groove and a PLC are mounted on one side, far away from the transparent experiment box, of the case. According to the utility model, the low-temperature storage cavity and the like are arranged; a user can respectively clamp a test tube filled with a hepatitis C genotyping detection reagent and some test tubes filled with samples to be detected into detection reagent storage grooves in the room-temperature storage cavities or the two low-temperature storage cavities with different temperatures according to the temperature requirements of a storage environment; and then the hepatitis C genotyping test paper is clamped into two test paper storage grooves in the room-temperature storage cavity for storage, so that the device has the advantage of classified storage, and experimental articles are convenient to store and flexible to take and use.

A method for estimating portal blood flow and hepatic function in a subject is provided. In one example, the STAT test is an in vitro simplified, convenient test intended for screening purposes that can reasonably estimate the portal blood flow from a single blood sample taken 60 minutes after orally administered deuterated-cholate. The test can be administered to a patient having, or suspected of having, Chronic Hepatitis C, Primary Sclerosing Cholangitis (PSC), Non-Alcoholic Fatty Liver Disease (NAFLD), or any chronic liver disease.

The present invention discloses an anti-HCV core antigen monoclonal antibody, a hybridoma cell line and their applications. Specifically, a hybridoma cell line screened against the common conserved sequence of the core proteins of different genotypes of HCV, and the antibody secreted by it is used in the detection of HCV antigens, which can detect hepatitis C viruses of different genotypes, has good inclusiveness, and only two antibodies are needed to achieve the above technical effects. This can not only reduce the production cost of HCV antigen detection kits, but also reduce the production difficulty and improve the production efficiency.

The invention belongs to the technical field of nano-antibodies, and particularly relates to a nano-antibody for resisting galectin 3 binding protein as well as a preparation method and application of the nano-antibody. The galectin 3 binding protein is used as a research object, after being expressed and purified, the galectin 3 binding protein is used for immunizing alpaca, a phage display technology is used for screening to obtain the anti-galectin 3 binding protein nano antibody, and the antibody has high sensitivity and capacity of specifically binding with the galectin 3 binding protein. Through the preparation of the anti-galectin 3 binding protein nano antibody, a material is provided for establishing a diagnosis method for related diseases such as systemic lupus erythematosus, Behcet's disease, biliary tract cancer and hepatitis C.

The invention belongs to the biomedical technology, and particularly relates to a chimeric antigen receptor targeting HCC cells and application thereof, the chimeric antigen receptor comprises an extracellular domain, a transmembrane domain (TM) and an intracellular signal domain, and is characterized in that the extracellular domain comprises a GPC3 antigen binding domain, and the intracellular signal domain comprises a cytokine IL-7 and a chemotactic factor CCL19. Tumor antigen phosphatidylinositol proteoglycan 3 (GPC3) highly expressed on the surface of an HCC cell is selected as a main target spot of hepatocellular carcinoma CAR-T treatment, a second-generation GPC3-CAR-T cell is constructed, a transgenic cell factor IL-7 and a chemotactic factor CCL19 are increased to enter the CAR-T cell, and the cell factor IL-7 and the chemotactic factor have the effects of starting cell system immunity, promoting cell apoptosis, promoting cell apoptosis and the like. NK cells and cytotoxic T cells are gathered to a solid tumor area, and the problem that CAR-T cells are immersed into solid tumors is solved.